Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib

J Clin Oncol. 2008 Aug 20;26(24):4047-8. doi: 10.1200/JCO.2008.18.3525.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged, 80 and over
  • Antineoplastic Agents / adverse effects*
  • Benzenesulfonates / adverse effects*
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Renal Cell / drug therapy
  • Female
  • Humans
  • Indoles / adverse effects*
  • Kidney Neoplasms / drug therapy
  • Liver Neoplasms / drug therapy
  • Melanoma / drug therapy
  • Middle Aged
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Polycythemia / chemically induced*
  • Protein Kinase Inhibitors / adverse effects*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyridines / adverse effects*
  • Pyrroles / adverse effects*
  • Sorafenib
  • Sunitinib

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Indoles
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Pyridines
  • Pyrroles
  • Niacinamide
  • Sorafenib
  • Protein-Tyrosine Kinases
  • Sunitinib